好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Predictive Value of Cutaneous Biomarkers in Hereditary Transthyretin Amyloidosis
Neuromuscular and Clinical Neurophysiology (EMG)
S2 - Updates on Motor Neuron and Peripheral Nerve Disorders (1:24 PM-1:36 PM)
003

To determine whether cutaneous amyloid deposition and small fiber densities predict long-term outcomes in hereditary transthyretin amyloidosis (ATTRv) and to assess disease progression following tafamidis discontinuation.

ATTRv is a progressive multisystem disorder caused by pathogenic TTR variants. With disease-modifying therapies available, prognostic biomarkers are needed to guide treatment decisions. Skin biopsy enables evaluation of amyloid deposition and somatic and autonomic innervation, but its prognostic value remains uncertain.

We evaluated 40 ATTRv patients originally enrolled in a four-year tafamidis trial (30 treated, 10 untreated). Survival analyses included all 40 patients, while long-term progression and nutritional outcomes were evaluated in the 21 with extended follow-up (median 8 years, range 7–11; all previously tafamidis-treated). Baseline distal leg and thigh skin biopsies were analyzed for amyloid deposition [Amyloid Deposition Index (ADI)] and intraepidermal (IENFD), sweat gland (SGNFD), and pilomotor (PMNFD) nerve fiber density. Associations with disease progression and survival were tested.

At baseline, 70% had a polyneuropathy disease (PND) score of 0, and 27% of I. Among the 21 patients with long-term follow-up, 33% remained stage 0, while 48% progressed to stage I and 19% to stage IIIa–IV. Nutritional status declined after tafamidis withdrawal (modified body mass index, p=0.00028). In the full 40-patient cohort, higher ADI predicted mortality (total ADI odds ratio [OR] 1.03, 95% confidence interval 1.003-1.05, p=0.030; thigh ADI OR 1.05, 1.003-1.10, p=0.037), with consistent trends after age adjustment. Greater SGNFD (OR 0.84, 0.73-0.97, p=0.016) and PMNFD (OR 0.90, 0.83-0.97, p=0.006) were associated with reduced mortality; after adjustment, thigh PMNFD independently predicted survival (age-adjusted OR 0.90, 0.83–0.98, p=0.012).

Patients experienced progressive decline following tafamidis discontinuation. ADI was associated with mortality, underscoring the prognostic relevance of amyloid deposition, though its effect weakened after age adjustment. Pilomotor innervation independently predicted survival, reinforcing the prognostic value of skin biopsy in ATTRv.

Authors/Disclosures
Sara Massucco, MD
PRESENTER
Dr. Massucco has received research support from Italian Ministry of University and Research. Dr. Massucco has received research support from Beth Israel Deaconess Medical Center.
Roy L. Freeman, MD (Beth Israel Deaconess Hosp) Dr. Freeman has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Cutaneous Diagnostic Life Sciences. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vertex. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Theravance. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Inhibikase. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. The institution of Dr. Freeman has received research support from NIH. The institution of Dr. Freeman has received research support from Theravance. The institution of Dr. Freeman has received research support from Biohaven. The institution of Dr. Freeman has received research support from Lundbeck. Dr. Freeman has received research support from Regeneron.
Christopher H. Gibbons, MD, FAAN (Beth Israel Deaconess Medical Center) Dr. Gibbons has received personal compensation for serving as an employee of CND Life Sciences. Dr. Gibbons has or had stock in CND Life Sciences.Dr. Gibbons has received publishing royalties from a publication relating to health care.
Karla Cardenas-Soto, PhD Dr. Cardenas-Soto has nothing to disclose.
Maria Alejandra Gonzalez Duarte, MD, FAAN (NYU Dysautonomia Center) Dr. Gonzalez Duarte has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alnylam. Dr. Gonzalez Duarte has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra Zeneca. Dr. Gonzalez Duarte has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alnylam . The institution of Dr. Gonzalez Duarte has received research support from Pfizer.